

Supplementary table 1: Details of described cases of the included literature

Authors	Patient	Disease	Sex	Age (years)	Previous treatment	Daratumumab application	Daratumumab cumulative dosage	Concomitant treatment	Adverse events	Outcome	Autoantibody titer
Aggarwal et al. 2023[1]	1	aiTTP	female	64	Gc, PLEX, RTX, Capla, MMF, Borte	2x 1800mg/week sc	3600mg	Gc, Capla	NA	improvement	depletion
	2	aiTTP	female	59	Gc, PLEX, RTX, Capla, MMF, CsA	4x 16mg/kg/week iv	NA	Gc	NA	failure	reduction
Canales-Herrerias et al. 2022[2]	3	ITP	male	34	including Splenectomy, RTX, MMF, CsA, TPO-RA	7x 16mg/kg/week iv	NA	none	NA	remission	reduction
	4	ITP	female	35	including RTX	6x 16mg/kg/week iv	NA	none	NA	transient remission before relapse	reduction
	5	ITP	female	20	including RTX, Splenectomy	4x 16mg/kg/week iv	NA	none	NA	relapse	reduction before relapse
Crickx et al. 2021[3]	6	ITP	male	70	Gc, MMF, Sirol, CsA, Splenectomy	4x 16mg/kg/week iv	NA	Gc	mild reaction <sup>b,c</sup>	remission	not reported
	7	ITP	female	20	Gc, IVIG, Romiplostim, Eltrombopag, MMF, Disulone, Splenectomy	4x 16mg/kg/week iv	NA	Gc, IVIG	none <sup>c</sup>	failure	not reported
Dossier et al. 2021[4]	8	INS	male	6	Gc, Cl, RTX, Obi	1x 1000mg/1,73m <sup>2</sup> iv (after 1 dosage of Obi)	445mg	Tac	none <sup>a</sup>	remission	not reported
	9	INS	male	10.9	Gc, Cyc, MMF, Cl, Lev, RTX, Obi	1x 1000mg/1,73m <sup>2</sup> iv (after 1 dosage of Obi)	770mg	Gc	broncho-spasm <sup>b</sup> , throat itching <sup>b</sup> , labial edema <sup>b</sup>	relapse	not reported

Authors	Patient	Disease	Sex	Age (years)	Previous treatment	Daratumumab application	Daratumumab cumulative dosage	Concomitant treatment	Adverse events	Outcome	Autoantibody titer
	10	INS	male	9.5	Gc, MMF, CI, RTX, Obi	1x 1000mg/1,73m <sup>2</sup> iv (after 1 dosage of Obi)	800mg	Gc, CsA	urticaria <sup>b</sup> , neutropenia	remission	not reported
	11	INS	male	13.7	Gc, MMF, CI, Lev, RTX, Ofa, Obi	1x 1000mg/1,73m <sup>2</sup> iv (after 1 dosage of Obi)	820mg	Tac	vomiting <sup>b</sup> hypogammaglobulinemia	remission	not reported
	12	INS	male	10.9	Gc, MMF, CI, RTX, Obi	1x 1000mg/1,73m <sup>2</sup> iv (after 1 dosage of Obi)	750mg	Gc	none <sup>a</sup>	remission	not reported
	13	INS	female	14.7	Gc, Cyc, MMF, CI, Lev, RTX, Obi	1x 1000mg/1,73m <sup>2</sup> iv (after 1 dosage of Obi)	870mg	Gc	none <sup>a</sup>	remission	not reported
	14	INS	male	18.8	Gc, Cyc, MMF, CI, Lev, RTX, Obi	1x 1000mg/1,73m <sup>2</sup> iv (after 1 dosage of Obi)	1000mg	Gc	hypogammaglobulinemia	remission	not reported
	15	INS	male	10.3	Gc, MMF, CI, Lev, RTX, Obi	1x 1000mg/1,73m <sup>2</sup> iv (after 1 dosage of Obi)	700mg	Tac	hypogammaglobulinemia	relapse	not reported
	16	INS	male	14.7	Gc, MMF, CI, Lev, RTX, Obi	1x 1000mg/1,73m <sup>2</sup> iv (after 1 dosage of Obi)	900mg	Tac	neutropenia, hypogammaglobulinemia	remission	not reported
	17	INS	male	10.5	Gc, MMF, CI, RTX; Ofa, Obi	1x 1000mg/1,73m <sup>2</sup> iv (after 1 dosage of Obi)	680mg	Gc, Tac	vomiting <sup>b</sup> , hypogammaglobulinemia	relapse	not reported
	18	INS	male	11.2	Gc, MMF, Lev, RTX, Obi	1x 1000mg/1,73m <sup>2</sup> iv (after 1 dosage of Obi)	600mg	Gc, Tac	none <sup>a</sup>	relapse	not reported
	19	INS	male	11	Gc, MMF, CI, Lev, RTX; Ofa, Obi	1x 1000mg/1,73m <sup>2</sup> iv (after 1 dosage of Obi)	770mg	Gc, Tac	broncho-spasm <sup>b</sup> , throat itching <sup>b</sup> , labial edema <sup>b</sup>	remission	not reported

Authors	Patient	Disease	Sex	Age (years)	Previous treatment	Daratumumab application	Daratumumab cumulative dosage	Concomitant treatment	Adverse events	Outcome	Autoantibody titer
	20	INS	male	15.7	Gc, MMF, CI, RTX, Obi	1x 1000mg/1,73m <sup>2</sup> iv (after 1 dosage of Obi)	750mg	Gc	broncho-spasm <sup>b</sup> , throat itching <sup>b</sup> , labial edema <sup>b</sup>	remission	not reported
	21	INS	male	9.7	Gc, CI, RTX, Obi	1x 1000mg/1,73m <sup>2</sup> iv (after 1 dosage of Obi)	580mg	Gc, Tac	broncho-spasm <sup>b</sup> , throat itching <sup>b</sup> , labial edema <sup>b</sup>	relapse	not reported
<b>Dossier et al. 2022[5]</b>	22-27	3 FSGS 3 MCD	4 male 2 female	6.1	CsA or Tac, MMF in 4 patients, RTX or Obi, IA	4x 1000mg/1,73m <sup>2</sup> iv	NA	Obi	NA	remission	not reported
<b>Gangat et al. 2022[6]</b>	28	acquired idiopathic PRCA	female	74	Gc, CsA, RTX, ATG, Alemtuzumab, Cyc, Borte, Eltrombopag, Danazol	XYx 16mg/kg/week for 8 weeks, then every 2 weeks, then monthly iv	NA	none	upper respiratory tract infection	remission	not reported
<b>Holzer et al. 2023[7]</b>	29	MDA5+ DM	male	19	Gc, IVIG, Cyc, Tofa, MMF, RTX, CsA, Anakinra	4x 1800mg/week sc	7200mg	Gc	none	remission	depletion
<b>Jain et al. 2020[8]</b>	30	AIHA	female	60	Gc, Aza, RTX	4x 16mg/kg/week iv	NA	Gc, RTX, Splenectomy	none	transient remission before relapse	not reported
<b>Krusche et al. 2023[9]</b>	31	PR3+ GPA	female	29	Gc, Cyc, RTX, PLEX	4x1800mg/week sc	7200mg	Gc, ECMO	none	remission	reduction
<b>Landon-Cardinal et al. 2023[10]</b>	32	SRP+ IMNM	male	27	Gc, MTX, IVIG, RTX, PLEX, Tac	XYx 16mg/kg/week for 8 weeks, then every 2 weeks, then monthly iv	NA	Gc, IVIG, MTX, Tac	hypogammaglobulinemia mild infection	remission	reduction
<b>Liu et al. 2023[11]</b>	33	acquired hemophilia A	female	37	Gc, CsA, HCO, Cyc, MMF	12x 4mg/kg/week, then 8x 8mg/kg/week iv	NA	Gc	none	remission	depletion

Authors	Patient	Disease	Sex	Age (years)	Previous treatment	Daratumumab application	Daratumumab cumulative dosage	Concomitant treatment	Adverse events	Outcome	Autoantibody titer
	34	acquired hemophilia A	male	32	Gc, Cyc, RTX	9x 8mg/kg/week iv	NA	Gc	none	remission	depletion
	35	acquired hemophilia A	male	73	Gc, Cyc, Borte, Zanubrutinib	1x 4mg/kg/week, then 12x 8mg/kg/week, then 5x 16mg/kg/week iv	NA	Gc	none	remission	reduction
	36	acquired hemophilia A	male	70	Gc, Cyc	14x 8mg/kg/week iv	NA	Gc	none	remission	reduction
<b>McGothlin et al. 2023[12]</b>	37	AIHA	female	64	Gc, RTX, Splenectomy	Xx iv	NA	NA	none	remission	not reported
<b>Mohamed et al. 2023[13]</b>	38	CAD	female	69	RTX	18x 16mg/kg/week iv	NA	EPO	fatigue <sup>b</sup>	remission	not reported
<b>Moonla et al. 2021[14], Moonla et al. 2019[15]</b>	39	acquired hemophilia A	male	21	RTX, PLEX, HD-ITI	8x 16mg/kg/week iv	NA	RTX, PLEX, ITI	hypogammaglobulinemia	improvement	depletion
<b>Moonla et al. 2021[14]</b>	40	acquired hemophilia A	NA	18	HD-ITI	5x 16mg/kg/week iv	NA	HD-ITI, LD-ITI	NA	improvement	depletion
	41	acquired hemophilia A	NA	16	HD-ITI	6x 16mg/kg/week iv	NA	RTX, PLEX, HD-ITI, Gc	Sepsis, pneumonia, RTX-induced pneumonitis	death	no effect
<b>Moonla et al. 2022[16]</b>	42	acquired hemophilia A	male	33	Gc, Cyc	4x 16mg/kg/week iv	NA	Gc	transient hypogammaglobulinemia	remission	depletion

Authors	Patient	Disease	Sex	Age (years)	Previous treatment	Daratumumab application	Daratumumab cumulative dosage	Concomitant treatment	Adverse events	Outcome	Autoantibody titer
<b>Moonla et al. 2023[17]</b>	43	acquired hemophilia A	male	35	Gc, Factor VII, Prothrombin, Cyc	4x 16mg/kg/week iv	NA	Gc, Cyc po, Factor VII, Prothrombin	transient hypogammaglobulinemia	remission	depletion
<b>Mutlu et al. 2023[18]</b>	44	SLE with cerebral vasculitis	female	39	Gc, HCQ, RTX, Bel, Upa, Cyc, MMF	4x 1800mg/week sc	7200mg	Gc, Bel	none	improvement	depletion
<b>Nocturne et al. 2023[19]</b>	45	Primary SjD with hyperchylomicronemia	female	18	RTX	4x 1800mg/week sc	7200mg	none	none	remission	reduction
	46	Primary SjD with cryoglobulinemia	female	68	RTX, Cyc, Bel	4x 1800mg/week sc	7200mg	none	none	remission	reduction
<b>Ochoa et al. 2021[20]</b>	47	anti-IFN $\gamma$ antibodies in MOTT infection	female	31	RTX, anti-MOTT therapy, Borte	5x 16mg/kg/week iv	NA	IVIg	dyspnea <sup>b</sup> , urticaria <sup>b</sup> , hypogammaglobulinemia lymphocytic meningitis without detection of pathogens	improvement	reduction
<b>Ostendorf et al. 2020[21], Alexander et al. 2023[22]</b>	48	SLE with LN	female	50	Gc, Aza, MMF, CsA, Borte, Cyc	4x 16mg/kg/week iv	NA	Gc, MMF, Bel, IVIg	hypogammaglobulinemia	improvement	reduction
	49	SLE	female	32	Gc, IVIg, MMF, Cyc, HCQ, Bel, RTX, PLEX, Borte	4x 16mg/kg/week iv	NA	Gc, Bel	upper respiratory tract infection	improvement	reduction
<b>Ostendorf et al. 2023[23]</b>	50	MPO+ MPA	male	57	Gc, Cyc, RTX	4x 1800mg/week sc, 2 <sup>nd</sup> cycle with 4x after 4 months	14400mg	NA	upper respiratory tract infection	remission	reduction

Authors	Patient	Disease	Sex	Age (years)	Previous treatment	Daratumumab application	Daratumumab cumulative dosage	Concomitant treatment	Adverse events	Outcome	Autoantibody titer
	51	PR3+ GPA	male	41	Gc, Cyc, RTX, PLEX, ECMO	4x 1800mg/week sc	7200mg	IVIG	hypogammaglobulinemia	remission	reduction
<b>Ostendorf et al. 2023[24]</b>	52	MDA5+ DM	female	55	Gc, Tofa, CsA, IVIG, Cyc, ECMO	4x 1800mg/week sc	7200mg	Gc, Tofa, CsA, IVIG, ECMO	blood stream infection	improvement	depletion
<b>Pereda et al. 2022[25]</b>	53	red cell antibodies inducing hemolytic transfusion reaction in sickle cell disease	female	17	Gc, RTX	6x 16mg/kg/week iv	NA	none	none	remission	depletion
<b>Plequezuelo et al. 2021[26]</b>	54	primary APS	female	21	Anticoagulation, HCQ, PLEX, IVIG	4x 8mg/kg/week, then 16mg/kg/week iv	NA	Anticoagulation, IVIG	mild diarrhea <sup>b</sup> , one upper respiratory tract infection, transient hypogammaglobulinemia	improvement	reduction
<b>Ratuszny et al. 2020[27]</b>	55	NMDA-R+ encephalitis	female	20	Gc, RTX, PLEX, IVIG, Cyc, Borte	8x 16mg/kg/week for 8 weeks, then 2x every 2 weeks iv	8000mg	Gc, IVIG, later Borte, RTX	NA	improvement	no effect
<b>Rieger et al. 2021[28]</b>	56	AIHA	female	44	Gc, IVIG, RTX, Hematopoiesis stimulating agents, Splenectomy, Cyc, MMF	6x 16mg/kg/week iv, 2nd cycle after some months	NA	Eltrombopag	NA	remission	not reported
	57	AIHA	female	55	Gc, RTX	6x 16mg/kg/week iv	NA	Gc	NA	transient remission before relapse	not reported

Authors	Patient	Disease	Sex	Age (years)	Previous treatment	Daratumumab application	Daratumumab cumulative dosage	Concomitant treatment	Adverse events	Outcome	Autoantibody titer
<b>Rixecker et al. 2023[29]</b>	58	PR3+ GPA	male	NA	Gc, RTX, Cyc, PLEX, ECMO, Avacopan	6x 16mg/kg/week iv	NA	Gc, Cyc, ECMO, Avacopan	NA	remission	depletion
<b>Roccatello et al. 2023[30]</b>	59	LN	male	41	Gc, RTX, Cyc, Bel, Aza	8x 16mg/kg/week for 8 weeks, then 4x every 2 weeks, then 10x every month iv	NA	Gc	asymptomatic SARS-CoV2-infection	3x remission 2x improvement	reduction
	60	LN	female	24	Gc, MMF, RTX, Cyc	8x 16mg/kg/week for 8 weeks, then 4x every 2 weeks, then 10x every month iv	NA	Gc	none		reduction
	61	LN	female	61	Gc, RTX, Cyc	8x 16mg/kg/week for 8 weeks, then 4x every 2 weeks, then 10x every month iv	NA	Gc	none		reduction
	62	LN	female	20	Gc, MMF, RTX, CsA, Bel	8x 16mg/kg/week for 8 weeks, then 4x every 2 weeks, then 10x every month iv	NA	Gc	mild redness <sup>b</sup> , asymptomatic SARS-Cov2		reduction
	63	LN	female	54	Gc, MMF, IVIG, Bel	8x 16mg/kg/week for 8 weeks, then 4x every 2 weeks, then 10x every month iv	NA	Gc	none		reduction
	64	LN	female	28	Gc, RTX, Cyc, Ocrelizumab	Xx 16mg/kg/week for 8 weeks, then every 2 weeks, then every month iv	NA	Gc	none	failure	not reported

Authors	Patient	Disease	Sex	Age (years)	Previous treatment	Daratumumab application	Daratumumab cumulative dosage	Concomitant treatment	Adverse events	Outcome	Autoantibody titer
<b>Rottländer et al. 2022[31]</b>	65	SLE	female	74	Gc, HCQ, Aza, Cyc, MMF, RTX, IVIG	4x 8mg/kg/week iv	NA	none	NA	remission	not reported
<b>Scheibe et al. 2022[32], Scheibe et al. 2020[33]</b>	66	CASPR2-encephalitis	male	57	Gc, PLEX, IA, IVIG, RTX, Borte	8x 16mg/kg/week for 8 weeks, then 4x every 2 weeks, then 1x after 1 month iv	NA	Gc, PLEX, RTX, IVIG	hypogammaglobulinemias epsis	death	reduction
<b>Scheibe et al. 2022[32]</b>	67	CASPR2-encephalitis	male	66	Gc, PLEX, RTX	8x 16mg/kg/week iv	NA	Gc, RTX, PLEX, IVIG	hypogammaglobulinemias infections including sepsis	death	reduction
	68	NMDA-R+ encephalitis	male	16	Gc, PLEX, IA, IVIG, RTX	6x 16mg/kg/week iv	NA	Gc, IVIG, Borte	fever <sup>b</sup> , tracheobronchitis <sup>b</sup> , hypogammaglobulinemia	improvement	depletion
	69	AE	male	59	Gc, PLEX, IVIG, RTX	8x 16mg/kg/week iv	NA	Gc, IVIG, RTX	tracheobronchitis <sup>b</sup> , fever <sup>b</sup> , tachycardia and -pnea <sup>b</sup> , fungemia, hypogammaglobulinemia	improvement	not applicable
	70	AE	female	27	Gc, PLEX, IVIG, RTX	4x 16mg/kg/week iv	NA	Gc, RTX, Aza	inflammatory serology without	improvement	depletion



Authors	Patient	Disease	Sex	Age (years)	Previous treatment	Daratumumab application	Daratumumab cumulative dosage	Concomitant treatment	Adverse events	Outcome	Autoantibody titer
	71	CIDP	male	52	Gc, PLEX, IVIG, RTX	8x 16mg/kg/week for 8 weeks, then 12x 16mg/kg/month iv	NA	Gc, MTX, IVIG	clinical infection dyspnea, night sweat, fever <sup>b</sup> , blood stream infection, hypogammaglobulinemia	improvement	depletion
	72	seronegative MG	male	54	Gc, IVIG, PLEX, IA, Aza, MMF, MTX, RTX, Eculizumab	8x 16mg/kg/week for 8 weeks, then 4x every 2 weeks, then 8x every month iv	NA	Gc, PLEX, IVIG	dyspnea <sup>b</sup> , tachycardia <sup>b</sup> , fatigue, muscle pain, hypogammaglobulinemia	improvement	not applicable
<b>Strüßmann et al. 2023[34]</b>	73	ITP	male	39	Gc, Splenectomy, Eltrombopag, Romiplostim, RTX, Fostamatinib, IVIG	3x 1800mg/week sc	5400mg	none	NA	remission	not reported
<b>van den Beerg et al. 2022[35]</b>	74	aiTTP	male	32	Gc, PLEX, RTX, Capla	4x 16mg/kg/week iv	NA	Gc	none	remission	depletion
	75	aiTTP	female	31	Gc, PLEX, RTX, Capla	6x 16mg/kg/week iv	NA	Capla	none	remission	depletion
<b>Vernava et al. 2023[36]</b>	76	ITP	female	82	Gc, IVIG, Eltrombopag, RTX	8x 16mg/kg/week for 16 weeks, then 4x every 2 weeks iv	NA	Gc, IVIG	hypogammaglobulinemia	remission	not reported
	77	ITP	male	54	Gc, Romiplostim sc, Eltrombopag, RTX, IVIG	8x 16mg/kg/week iv	NA	Gc, Fostamatinib	dyspnea <sup>b</sup> , flush <sup>b</sup>	stabilization without improvement	not reported
<b>Vink et al. 2022[37]</b>	78	PLAR2+ membranous nephropathy	female	38	Gc, MMF, RTX, Cyc, Bort	8x 16mg/kg/week for 8 weeks, then 6x every 2 weeks iv	NA	RTX, Borte	NA	improvement	reduction

Authors	Patient	Disease	Sex	Age (years)	Previous treatment	Daratumumab application	Daratumumab cumulative dosage	Concomitant treatment	Adverse events	Outcome	Autoantibody titer
Xie et al. 2023[38]	79	aiTTP	female	35	Gc, PLEX, RTX	1x 100mg iv	100mg	Gc, PLEX, RTX	none	remission	depletion
	80	aiTTP	female	53	Gc, PLEX, RTX	1x 100mg iv	100mg	Gc, PLEX, RTX	none	relapse, after 5 more treatment rounds	remission not measured
	81	aiTTP	female	48	Gc, PLEX, RTX	1x 100mg iv	100mg	Gc, PLEX, RTX	none	remission	no effect
	82	aiTTP	female	52	Gc, PLEX, RTX	1x 100mg iv	100mg	Gc, PLEX, RTX	oral soor	remission	depletion
	83	aiTTP	male	71	Gc, PLEX	1x 100mg iv	100mg	Gc, PLEX, RTX	none	exacerbation, after 11 more treatment rounds	remission depletion

Abbreviations (alphabetically sorted): AE = autoimmune encephalitis, AIHA = autoimmune hemolytic anemia, APS = anti-phospholipid-syndrome, aiTTP = acquired immune mediated thrombotic thrombocytopenic purpura, ATG = anti-thymocyte globulin, Aza = azathioprine, Bel = belimumab, Borte = bortezomib, CAD = Cold agglutinin disease, Capla = caplacizumab, CI = calcineurin inhibitor, CIDP = chronic inflammatory demyelinating disease, CsA = ciclosporin A, Cyc = cyclophosphamide, DM = dermatomyositis, ECMO = extracorporeal membrane oxygenation, EPO = erythropoietin, Gc = glucocorticoids, GPA = granulomatosis with polyangiitis, HD/LD-ITI = high dose/low dose immune tolerance induction (=Factor VIII), HCQ = hydroxychloroquine, IA = immunoadsorption, IFN $\gamma$  = interferon  $\gamma$ , IMNM = immune mediated necrotizing myopathy, INS = idiopathic nephrotic syndrome, ITP = immune thrombocytopenic purpura, iv = intravenous, IVIG = intravenous immunoglobulin, Lev = levamisole, LN = lupus nephritis, MG = myasthenia gravis, MMF = mycophenolate mofetil, MOTT = mycobacteria other than tuberculosis, MPA = microscopic polyangiitis, MTX = methotrexate, NA = not reported, Obi = Obinutuzumab, Ofa = ofatumumab, PLEX = plasmapheresis, PRCA = pure red cell aplasia, RTX = rituximab, sc = subcutaneous, Sirol = sirolimus, SjD = Sjögren's disease, SLE = systemic lupus erythematosus, Tac = tacrolimus, Tofa = tofacitinib, TPO-RA = thrombopoietin receptor agonists, Upa = upadacitinib

<sup>a</sup>: 2 of 4 patients with no adverse events had hypogammaglobulinemia

<sup>b</sup>: infusion reaction

<sup>c</sup>: hypogammaglobulinemia in most patients, not stated which

Supplementary table 2: Active, recruiting or planned clinical trials for daratumumab in autoimmune diseases (clinicaltrials.gov on 25<sup>th</sup> of June 2023)

NCT Number	Study Title	Study Status	Conditions	Interventions	Study Type
<b>NCT05671757</b>	Daratumumab in Primary Antiphospholipid Syndrome	recruiting	Autoimmune Disorders	BIOLOGICAL: Daratumumab	interventional
<b>NCT04868838</b>	Daratumumab to Treat Active Lupus Nephritis	recruiting	Lupus Nephritis	DRUG: Daratumumab	interventional
<b>NCT04810754</b>	An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus	not yet recruiting	Systemic Lupus Erythematosus	DRUG: Daratumumab Injection	interventional
<b>NCT04703621</b>	The DART Study- Daratumumab Treatment in ITP	recruiting	ITP	DRUG: Daratumumab Injection	interventional
<b>NCT05562882</b>	A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia	not yet recruiting	Immune Thrombocytopenia	DRUG: Daratumumab Injection	interventional
<b>NCT05403138</b>	Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders	recruiting	Neuromyelitis Optica	DRUG: Daratumumab   DRUG: Placebo	interventional
<b>NCT04070378</b>	Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease	active, not recruiting	Alzheimer Disease	DRUG: Daratumumab Injection	interventional
<b>NCT05486481</b>	Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11)	not yet recruiting	AL Amyloidosis	DRUG: Venetoclax   DRUG: Dexamethasone   DRUG: Daratumumab,	interventional
<b>NCT04895917</b>	Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis	recruiting	AL Amyloidosis	DRUG: daratumumab and pomalidomide	interventional
<b>NCT04270175</b>	Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab	recruiting	AL Amyloidosis	DRUG: Daratumumab   DRUG: Pomalidomide   DRUG: Dexamethasone	interventional

NCT Number	Study Title	Study Status	Conditions	Interventions	Study Type
<b>NCT05004259</b>	The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia	recruiting	Hemolytic Anemia	DRUG: Daratumumab / Hyaluronidase Injection	interventional
<b>NCT03283917</b>	Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis	active, not recruiting	Newly Diagnosed/Recurrent or refractory Primary Amyloidosis	BIOLOGICAL: Daratumumab DRUG: Dexamethasone DRUG: Ixazomib	interventional
<b>NCT04474938</b>	Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis	active, not recruiting	Amyloidosis	DRUG: Daratumumab DRUG: Bortezomib DRUG:Dexamethasone	interventional
<b>NCT05888870</b>	ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor	recruiting	Hemophilia A With Inhibitor	DRUG: SCT800 and Daratumumab DRUG: SCT800	interventional
<b>NCT05250973</b>	A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis	recruiting	Amyloidosis	DRUG: Daratumumab DRUG: Cyclophosphamide DRUG: Bortezomib DRUG: Dexamethasone	interventional
<b>NCT05849740</b>	An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A	recruiting	Acquired Hemophilia	DRUG: Daratumumab and corticosteroid treatment	interventional
<b>NCT04131309</b>	A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis	active, not recruiting	Light Chain (AL) Amyloidosis, Stage 3B	DRUG: Daratumumab DRUG: Bortezomib Injection DRUG: Dexamethasone oral tablet	interventional
<b>NCT05704400</b>	Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome	not yet recruiting	Nephrotic Syndrome	DRUG: Rituximab Biosimilar ABP 798 DRUG: Daratumumab	interventional

NCT Number	Study Title	Study Status	Conditions	Interventions	Study Type
<b>NCT03201965</b>	A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis	active, not recruiting	Amyloidosis	DRUG: Cyclophosphamide DRUG: Bortezomib DRUG: Dexamethasone, 40 mg DRUG: Daratumumab	interventional
<b>NCT05898646</b>	Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial	not yet recruiting	AL Amyloidosis	PROCEDURE: Bone Marrow Biopsy BIOLOGICAL: Daratumumab PROCEDURE: Echocardiography OTHER: Questionnaire Administration PROCEDURE: X-Ray Imaging	interventional
<b>NCT05065970</b>	Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy	active, not recruiting	Immunoglobulin A (IgA) Nephropathy	DRUG: Felzartamab OTHER: Placebo	interventional
<b>NCT05277493</b>	A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab	recruiting	AL Amyloidosis	-	observational

## REFERENCES

- 1 Aggarwal A, White D, Pavord S, et al. Daratumumab for refractory immune-mediated thrombotic thrombocytopenic purpura. *Br J Haematol* 2023. doi:10.1111/bjh.18854 [published Online First: 14 May 2023].
- 2 Canales-Herrerias P, Crickx E, Broketa M, et al. High-affinity autoreactive plasma cells disseminate through multiple organs in patients with immune thrombocytopenic purpura. *J Clin Invest* 2022;132(12).
- 3 Crickx E, Audia S, Robbins A, et al. Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia. *Haematologica* 2021;106(12):3198–201. doi:10.3324/haematol.2021.279232 [published Online First: 1 December 2021].

- 4 Dossier C, Prim B, Moreau C, et al. A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. *Pediatr Nephrol* 2021;36(5):1175–82. doi:10.1007/s00467-020-04811-0 [published Online First: 28 October 2020].
- 5 Dossier C, Leclerc A-L, Fila M, et al. Abstracts of the 54th ESPN Annual Meeting, Ljubljana, Slovenia: DARATUMUMAB ENABLES SUSTAINED REMISSION AFTER IMMUNOADSORPTION IN REFRACTORY MULTIDRUG RESISTANT NEPHROTIC SYNDROME. *Pediatr Nephrol* 2022;37(11):2803–969.
- 6 Gangat N, Bleeker J, Lynch D, et al. Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia. *Haematologica* 2022;107(10):2523–26. doi:10.3324/haematol.2022.281398 [published Online First: 1 October 2022].
- 7 Holzer M-T, Nies JF, Oqueka T, et al. Successful Rescue Therapy With Daratumumab in Rapidly Progressive Interstitial Lung Disease Caused by MDA5-Positive Dermatomyositis. *Chest* 2023;163(1):e1-e5.
- 8 Jain A, Gupta DK. Daratumumab for refractory warm autoimmune hemolytic anemia. *Ann Hematol* 2021;100(5):1351–53. doi:10.1007/s00277-020-04063-w [published Online First: 14 May 2020].
- 9 Krusche M, Oqueka T, Wichman D, et al. Daratumumab as rescue therapy in life-threatening granulomatosis with polyangiitis. *Rheumatology (Oxford)* 2023. doi:10.1093/rheumatology/kead474 [published Online First: 9 September 2023].
- 10 Landon-Cardinal O, Allard-Chamard H, Chapdelaine H, et al. Daratumumab as a rescue therapy in severe refractory anti-SRP immune-mediated necrotising myopathy. *Ann Rheum Dis* 2023. doi:10.1136/ard-2022-223541 [published Online First: 6 January 2023].
- 11 Liu W, Liu J, Xue F, et al. Anti-CD38 antibody for refractory acquired hemophilia A. *J Thromb Haemost* 2023;21(6):1515–18. doi:10.1016/j.jtha.2023.03.010 [published Online First: 20 March 2023].
- 12 McGlothlin J, Abeykoon J, Al-Hattab E, et al. Bortezomib and daratumumab in refractory autoimmune hemolytic anemia. *Am J Hematol* 2023;98(10):E263-E265. doi:10.1002/ajh.27025 [published Online First: 7 July 2023].
- 13 Mohamed A, Alkhatib M, Alshurafa A, et al. Refractory cold agglutinin disease successfully treated with daratumumab. A case report and review of literature. *Hematology* 2023;28(1):2252651.
- 14 Moonla C, Uaprasert N, Watanaboonyongcharoen P, et al. Daratumumab rapidly reduces high-titre factor VIII inhibitors in haemophilia A patients during life-threatening haemorrhages. *Haemophilia* 2021;27(1):e155-e159. doi:10.1111/hae.14118 [published Online First: 25 August 2020].
- 15 Moonla C, Polprasert C, Krittikarux S, Krajbithong S, Chajuwan T, Sukperm A, Akkawat B, Rojnuckarin P, Uaprasert N. Daratumumab as an Adjunctive Therapy for Acquired Hemophilia A with Poor Prognostic Markers [abstract]. <https://abstracts.isth.org/abstract/daratumumab-as-an-adjunctive-therapy-for-acquired-hemophilia-a-with-poor-prognostic-markers/>. Accessed July 10, 2023.
- 16 C. Moonla, N. Uaprasert, P. Watanaboonyongchroen, R. Jantasing, M. Meesanun, A. Sukperm, S. Faknuam, P. Kaewphichai, S. Sutthinont, P. Cheankiln, B. Akkawat, U. Bunworasate, P. Rojnuckarin. Daratumumab in Combination with Rituximab and Immune Tolerance Induction Can Rapidly Eradicate High-titer Factor VIII Inhibitor in a Patient with Hemophilia A. <https://academy.isth.org/isth/2019/melbourne/263428/chatphatai.moonla.daratumumab.in.combination.with.rituximab.and.immune.html> on 10 July 2023.

- 17 Moonla C, Polprasert C, Krittikarux S, et al. Adjunctive daratumumab can induce rapid remission in acquired haemophilia A with poor prognostic markers. *Haemophilia* 2023. doi:10.1111/hae.14850 [published Online First: 4 September 2023].
- 18 Yalcin Mutlu M, Wacker J, Tascilar K, et al. Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus-associated refractory cerebral vasculitis induces immune tolerance. *Rheumatology (Oxford)* 2023;62(2):e21-e23.
- 19 Nocturne G, Marmontel O, Di Filippo M, et al. Efficacy of daratumumab in refractory primary Sjögren disease. *RMD Open* 2023;9(3).
- 20 Ochoa S, Ding L, Kreuzburg S, et al. Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient With Anti-Interferon- $\gamma$  Autoantibodies. *Clin Infect Dis* 2021;72(12):2206–08.
- 21 Ostendorf L, Burns M, Durek P, et al. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. *N Engl J Med* 2020;383(12):1149–55.
- 22 Alexander T, Ostendorf L, Biesen R, et al. Sustained responses after anti-CD38 treatment with daratumumab in two patients with refractory systemic lupus erythematosus. *Ann Rheum Dis* 2023. doi:10.1136/ard-2023-224152 [published Online First: 3 July 2023].
- 23 Ostendorf L, Burns M, Wagner DL, et al. Daratumumab for the treatment of refractory ANCA-associated vasculitis. *RMD Open* 2023;9(1).
- 24 Ostendorf L, Muench F, Thormählen L, et al. Rescue combination treatment of anti-MDA5-associated ARDS with daratumumab. *RMD Open* 2023;9(3).
- 25 Pereda MA, Hosahalli Vasanna S, Desai NJ, et al. Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia. *Front Immunol* 2022;13:1055473. doi:10.3389/fimmu.2022.1055473 [published Online First: 29 November 2022].
- 26 Pleguezuelo DE, Díaz-Simón R, Cabrera-Marante O, et al. Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome. *Front Immunol* 2021;12:667515. doi:10.3389/fimmu.2021.667515 [published Online First: 12 April 2021].
- 27 Ratuszny D, Skripuletz T, Wegner F, et al. Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis. *Front Neurol* 2020;11:602102. doi:10.3389/fneur.2020.602102 [published Online First: 22 December 2020].
- 28 Rieger MJ, Stolz SM, Ludwig S, et al. Daratumumab in rituximab-refractory autoimmune haemolytic anaemia. *Br J Haematol* 2021;194(5):931–34. doi:10.1111/bjh.17655 [published Online First: 28 June 2021].
- 29 Rixecker TM, Lepper PM, Mang S, et al. Daratumumab for a Patient With Refractory Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. *JAMA Intern Med* 2023;183(6):615–18.
- 30 Roccatello D, Fenoglio R, Caniggia I, et al. Daratumumab monotherapy for refractory lupus nephritis. *Nat Med* 2023;29(8):2041–47. doi:10.1038/s41591-023-02479-1 [published Online First: 10 August 2023].
- 31 Rottländer Yella, Baumann Michael, Gramatzki Martin, Schmiedeberg Kristin, von Kempis Johannes, Rubbert-Roth Andrea. Successful treatment of refractory SLE-associated autoimmune hemolytic anemia with a low dose regimen using the CD38 directed monoclonal antibody daratumumab. *Swiss Medical Weekly* 2022;152 (Suppl. 261).
- 32 Scheibe F, Ostendorf L, Prüss H, et al. Daratumumab for treatment-refractory antibody-mediated diseases in neurology. *Eur J Neurol* 2022;29(6):1847–54. doi:10.1111/ene.15266 [published Online First: 10 February 2022].

- 33 Scheibe F, Ostendorf L, Reincke SM, et al. Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis. *J Neurol* 2020;267(2):317–23. doi:10.1007/s00415-019-09585-6 [published Online First: 19 October 2019].
- 34 Strüßmann T, Jung J, Heinz J, et al. Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab. *Ann Hematol* 2023;102(1):245–47. doi:10.1007/s00277-022-05035-y [published Online First: 17 November 2022].
- 35 van den Berg J, Kremer Hovinga JA, Pflieger C, et al. Daratumumab for immune thrombotic thrombocytopenic purpura. *Blood Adv* 2022;6(3):993–97.
- 36 Vernava I, Schmitt CA. Daratumumab as a novel treatment option in refractory ITP. *Blood Cells Mol Dis* 2023;99:102724. doi:10.1016/j.bcmd.2023.102724 [published Online First: 13 January 2023].
- 37 Vink CH, van Cranenbroek B, van der Heijden JW, et al. Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy. *Kidney Int* 2022;101(3):646–47.
- 38 Xie X-T, Xiao Y-Y, Zhang Y, et al. Combination regimens containing daratumumab for initial diagnosed acquired thrombotic thrombocytopenic purpura. *J Thromb Thrombolysis* 2023;55(2):399–405. doi:10.1007/s11239-023-02768-z [published Online First: 13 January 2023].